We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
18 Mar 2021 - 21 Mar 2021
13 Apr 2021 - 16 Apr 2021

Biomarker Predicts Pancreatic Cancer Patients’ Response to CD40 Immunotherapy

By LabMedica International staff writers
Posted on 17 Feb 2021
Print article
Image: The Z2 Coulter Counter Analyzer can be used to analyze virtually any cell type and species variation (Photo courtesy of Beckman Coulter).
Image: The Z2 Coulter Counter Analyzer can be used to analyze virtually any cell type and species variation (Photo courtesy of Beckman Coulter).
Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and currently the third leading cause of cancer deaths in the USA. Despite the fact that it only accounts for about 3% of new cancer cases, it is responsible for more than 7% of all cancer deaths, and only10% of patients survive five years with the disease.

The purpose of CD40 agonists is to help hasten and facilitate the immune system both by activating antigen-presenting cells, such as dendritic cells, to "prime" T cells and by enhancing anti-tumor macrophage activity. However, CD40 agonist-combination approaches only shrink tumors in a little more than half of patients, past studies have shown.

Hematology and Oncology specialists from the Abramson Cancer Center of the University of Pennsylvania (Philadelphia, PA, USA) analyzed blood samples from 22 patients with PDAC to gain insight into the immunological mechanisms underway after treatment with chemoimmunotherapy. Clinical data including demographics and characteristics and clinical laboratory tests were abstracted from the electronic medical record. Blood analyses were based on clinical chemistry and hematology laboratory analysis. Patients were defined as being non-inflamed (NLRlow) or systemically inflamed (NLRhigh) based on pre-treatment neutrophil-lymphocyte ratio (NLR) with a cutoff of greater or less than 3:1.

Plasma was collected and stored at -80 ⁰C until analysis. Cytokine levels (IL-2, IL4, IL-5, IL-1b, IL-6, IL-8, IL-10, IL-12, IFNγ, TNF) and Serum Amyloid A (SAA) levels were determined using human enzyme-linked immunosorbent assay kits. C-reactive protein (CRP) levels were determined by Cobas c311 assay (Roche Diagnostics, Indianapolis, IN, USA). Cryopreserved peripheral blood mononuclear cells (PBMCs) were thawed and counted using a Z2 Coulter Counter Analyzer (Beckman Coulter, Brea, CA, USA). CD14+ cells were isolated using positive selection with human CD14 microbeads. Mass cytometry antibody panel, staining and data acquisition was performed using a Helios mass cytometer (Fluidigm, South San Francisco, CA, USA).

The team observed a depletion of B cells, monocytes, and dendritic cells as well as activation of CD4+ T cells over eight days in most patients. Surprisingly, a closer look revealed no consistent evidence of CD8+ cell activation and no association between T cell activation and outcomes. These findings challenge preclinical studies that have suggested that T cell activation sparked by CD40 agonists would associate with outcomes.

Rather, overall survival outcomes were associated with a measurable characteristic in the patients' blood found before treatment: systemic inflammation. Systemic inflammation is marked by the increased presence of neutrophils, inflammatory cytokines (including IL-6 and IL-8) and acute phase reactants in the peripheral blood, and is a known symptom of pancreatic cancer and other cancer types. Patients with systemic inflammation before treatment with a CD40 agonist and gemcitabine, had a median overall survival of 5.8 months versus 12.3 months for patients without inflammation from the start of treatment.

Gregory L. Beatty, MD, PhD, an associate professor of Hematology-Oncology and senior author of the study said, “These latest findings support the fact that inflammation seems to place the immune system at a disadvantage and in doing so prevents the ability of immune therapies to work.” The study was published on January 26, 2021 in the journal JCI Insight.


Related Links:
Abramson Cancer Center of the University of Pennsylvania
Roche Diagnostics
Beckman Coulter
Fluidigm



Gold Supplier
COVID-19 Antibody Rapid Detection Kit
COVID-19 Antibody Rapid Detection Kit
New
Gold Supplier
POC Analyzer
Epithod 616
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System
New
Gold Supplier
Nucleic Acid Extractor (Magnetic Bead Method)
Singu20

Print article

Channels

Molecular Diagnostics

view channel
Image: Histopathologic image from a patient with Li Fraumeni syndrome showing accumulation of mutant TP53 in tumoral cells (Photo courtesy of Thierry Soussi, PhD).

Clinical Germline Testing Evaluated for Pediatric Cancer Patients

Pediatric cancer is rare, with fewer than 10,000 solid tumors diagnosed in children annually in the USA. Previous studies interrogating germline predisposition broadly across pediatric cancer types have... Read more

Industry

view channel
Illustration

Mindray and Tencent AI Lab to Jointly Develop AI Products for Blood Disease Screening and In Vitro Diagnosis

Shenzhen Mindray Biomedical Electronics Co., Ltd. (Shenzhen, China) has signed an AI cooperation framework agreement with Tencent AI Lab (Shenzhen, China) to jointly develop AI products for blood cell... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.